Neurogene (NGNE) Enterprise Value (2013 - 2026)
Neurogene's (NGNE) quarterly Enterprise Value came in at -$243.2 million in Q1 2026, up 16.89% YoY from -$208.0 million in Q1 2025, and up 9.6% on a QoQ basis from -$269.0 million in Q4 2025.
Neurogene (NGNE) Enterprise Value (2013 - 2026) Analysis & Trends
Neurogene (NGNE) has 14 years of Enterprise Value data on file, last reported at -$243.2 million in Q1 2026.
- Quarterly Enterprise Value rose 16.89% year-over-year to -$243.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$243.2 million (up 16.89% YoY) and the FY2025 annual result came in at -$269.0 million, up 13.89% from the prior year.
- Enterprise Value rose to -$243.2 million in Q1 2026, from -$269.0 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$78.5 million in Q3 2023 to a low of -$312.4 million in Q4 2024.
- A 5-year average of -$176.1 million and a median of -$153.9 million in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value jumped 42.43% — and 2023, when it plunged 140.37%.
- Tracing NGNE's Enterprise Value over 5 years: stood at -$82.0 million in 2022, then sank by 140.37% to -$197.2 million in 2023, then sank by 58.45% to -$312.4 million in 2024, then gained by 13.89% to -$269.0 million in 2025, then grew by 9.6% to -$243.2 million in 2026.
- The last three Enterprise Value figures came in at -$243.2 million (Q1 2026), -$269.0 million (Q4 2025), and -$265.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Neurogene | 815.03 Mn | 815.03 Mn | - | -225.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -225.39 Mn |
| Mar 31, 2026 | -243.18 Mn |
| Dec 31, 2025 | -269.01 Mn |
| Sep 30, 2025 | -265.41 Mn |
| Jun 30, 2025 | -274.52 Mn |
| Mar 31, 2025 | -292.60 Mn |
| Dec 31, 2024 | -312.41 Mn |
| Sep 30, 2024 | -138.99 Mn |
| Jun 30, 2024 | -153.91 Mn |
| Mar 31, 2024 | -169.53 Mn |
| Dec 31, 2023 | -197.16 Mn |
| Sep 30, 2023 | -78.51 Mn |
| Jun 30, 2023 | -82.06 Mn |
| Mar 31, 2023 | -83.44 Mn |
| Dec 31, 2022 | -82.02 Mn |
| Sep 30, 2022 | -106.88 Mn |
| Jun 30, 2022 | -116.46 Mn |
| Mar 31, 2022 | -128.06 Mn |
| Dec 31, 2021 | -142.47 Mn |
| Sep 30, 2021 | -154.92 Mn |